Sera

Sera Medicines is a biologics-focused accelerator headquartered in Boston, Massachusetts, that advances next-generation protein therapeutics to treat complex diseases with significant unmet medical needs through an innovative incubation and spinout model. Founded in October 2023 by RA Capital Management and members of Tenet Medicines management tea... m including Stephen Thomas, William Bonificio, and Naveen Daryani, the company operates as a platform that identifies, develops, and launches exceptional biotechnology companies focused on biologics innovation. Sera Medicines consists of a multidisciplinary team of experts in biology, chemistry, antibody engineering, drug discovery, manufacturing, clinical development, operations, and business development who combine their talents to create and advance promising therapeutic programs from discovery through clinical development. Once a program incubated at Sera achieves key value inflection milestones, the company enables rapid progression toward and beyond the clinic through the formation and financing of spinout companies. Sera Medicines has successfully launched multiple spinout companies including Tenet Medicines, which was acquired by Eliem Therapeutics in 2024, Navigator Medicines, which raised 100 million dollars in Series A financing in August 2024 to advance its bispecific antibody NAV-240 for autoimmune diseases, and Climb Bio, with over 300 million dollars in committed capital across these ventures. RA Capital Management has been the primary investor in Sera Medicines since its founding, holding approximately 81 percent of the company's equity interests, while members of Tenet's management hold approximately 19 percent. The company operates through Sera Services Inc, an affiliated entity that provides clinical development and professional services functions to its portfolio companies. Co-founded by Stephen Thomas, who serves as Chief Executive Officer and holds a PhD in Chemistry from Columbia University, and William Bonificio, who serves as Chief Business ...Read More